Risk of depressive episodes with rimonabant: A before and after modified prescription event monitoring study conducted in england

Drug Safety

Volumn 34, Issue 6, 2011, Pages 501-509

  Buggy, Yvonne ^a,b   Cornelius, Victoria ^a,b   Wilton, Lynda ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Depression; Depressive disorders; Prescription event monitoring; Psychiatric disorders; Rimonabant

Indexed keywords

RIMONABANT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MENTAL DISEASE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK; UNITED KINGDOM;

ADULT; COHORT STUDIES; DEPRESSIVE DISORDER; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, PRIMARY CARE; PIPERIDINES; PRESCRIPTIONS; PYRAZOLES; RISK FACTORS;

EID: 79956118608     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11588510-000000000-00000     Document Type: Article

References (32)

1. Sanofi-aventis. Acomplia: summary of product characteristics [online]. Available from URL: http://www.acom pliareport.com/AcompliaSPC.htm [Accessed 2011 Feb 18]
2. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissueofobese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63(4): 908-14 (Pubitemid 36368998)
3. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3 (9): 771-84 (Pubitemid 39242829)
4. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008; 13 (2): 196-212 (Pubitemid 351698889)
5. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Or-ganization, 2000
6. Rennie KL, Jebb SA. Prevalence of obesity in Great Britain. Obes Rev 2005; 6 (1): 11-2
7. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91 (3): 421-30 (Pubitemid 32049639)
8. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris prospective study. Int J Obes 1986; 10 (3): 229-40 (Pubitemid 16048558)
9. Dyer AR, Elliott P. The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-Operative Research Group. J Hum Hypertens 1989; 3 (5): 299-308 (Pubitemid 19247897)
10. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular dis-ease and death: 13-year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984; 288 (6428): 1401-4 (Pubitemid 14088431)
11. Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34 (10): 1055-8 (Pubitemid 16236528)
12. Kivimaki M, Lawlor DA, Singh-Manoux A, et al. Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study. BMJ 2009; 339: b3765
13. Kivimaki M, Batty GD, Singh-Manoux A, et al. Association between common mental disorder and obesity over the adult life course. Br J Psychiatry 2009; 195 (2): 149-55
14. Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg 2004; 14 (9): 1148-56 (Pubitemid 39458586)
15. Wadden TA, Sarwer DB, Womble LG, et al. Psychosocial aspects of obesity and obesity surgery. Surg Clin North Am 2001; 81 (5): 1001-24 (Pubitemid 32895997)
16. Roberts RE, Kaplan GA, Shema SJ, et al. Are the obese at greater risk for depression? Am J Epidemiol 2000; 152 (2): 163-70 (Pubitemid 30463664)
17. Roberts RE, Deleger S, Strawbridge WJ, et al. Prospective association between obesity and depression: evidence from the Alameda County study. Int J Obes Relat Metab Disord 2003; 27 (4): 514-21 (Pubitemid 36520852)
18. Ross CE. Overweight and depression. J Health Soc Behav 1994; 35 (1): 63-79
19. European Medicines Agency. European Medicines Agency recommends Acomplia must not be used in patients on antidepressants or with major depression [media release]. 2007 Jul 19 [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Press-relea se/2009/11/WC500012384.pdf [Accessed 2011 Apr 19]
20. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authori-sation of Acomplia [media release]. 2008 Oct 23 [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/Press-release/2009/11/WC500014774. pdf [Accessed 2011 Apr 19]
21. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365 (9468): 1389-97 (Pubitemid 40523733)
22. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipi-demia. N Engl J Med 2005; 353 (20): 2121-34 (Pubitemid 41653104)
23. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370 (9600): 1706-13 (Pubitemid 350100788)
24. Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 307-16
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington (VA): American Psychiatric Association, 2005
26. CIOMS-WHO. International guidelines for biomedical research involving human subjects. Geneva: CIOMS-WHO, 2002
27. Greenland S. Applications of stratified analysis methods. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA); Lippincott Williams and Wilkins, 2007: 281-99
28. Cummings P, McKnight B. Analysis of matched cohort data. Stata J 2006; 4 (3): 274-81
29. Medicines and Healthcare products Regulatory Agency. Rimonabant: depression; psychiatric reactions. Drug Saf Update 2008; 5 (10): 2-4
30. European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) [media release]. 2008 Oct 23 [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/Medicine-QA/2009/11/WC500014779.pdf [Accessed 2011 Apr 19]
31. McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ 1996; 313 (7059): 732-3
32. Office of National Statistics. Migration statistics 2008: annual report [online]. Available from URL: http://www. statistics.gov.uk/downloads/theme- population/Migration-Statistics-2008-Annual-Report.pdf [Accessed 2010 Feb 17]